Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden heart killer

NCT ID NCT06943365

Diagnosis Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a specific antibody in the blood can help diagnose and predict the course of a rare, life-threatening heart condition called short-coupled ventricular fibrillation (SCVF). Researchers will test 300 adults with SCVF for these antibodies and study how they affect heart cells. The goal is to develop a simple blood test to identify the condition and guide treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort study of SCVF probands

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of SCVF as per current criteria * Willingness to provide written informed consent Exclusion Criteria: \- SCVF patients \< age 18

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic ventricular fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

paroxysmal familial ventricular fibrillation Paroxysmal ventricular fibrillation torsade-de-pointes syndrome with short coupling interval

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic ventricular fibrillation Short-coupled ventricular fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    ACTIVE_NOT_RECRUITING

    Amsterdam, Netherlands

  • Institut universitaire de cardiologie et pneumologie de Québec

    RECRUITING

    Québec, Quebec, G1V4G5, Canada

  • Ottawa Heart Center

    NOT_YET_RECRUITING

    Ottawa, Ontario, Canada

  • PHRI

    ACTIVE_NOT_RECRUITING

    Hamilton, Ontario, Canada

  • St-Paul's Hospital - University of British Columbia

    NOT_YET_RECRUITING

    Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.